Zelboraf vemurafenib regulatory update

Chugai submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for Zelboraf vemurafenib to treat BRAF V600 mutation-positive melanoma. Chugai has Japanese rights to the oral small molecule inhibitor of the oncogenic BRAF V600E from Roche, which markets Zelboraf in the EU and U.S. for BRAF V600-mutation positive metastatic melanoma. Chugai is majority owned by Roche. Roche has rights to Zelboraf from Plexxikon Inc., which Daiichi Sankyo acquired in 2011. ...